NASDAQ : KRYS
Krystal Biotech, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 332.29 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.84B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.84B |
| Enterprise Value | 8.74B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 29.60M |
| Shares Outstanding | 29.60M |
| Shares Change (YoY) | +1.46% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 9.94% |
| Owned by Institutions (%) | 89.76% |
| Float | 23.62M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 41.72 |
| Forward PE | 42.32 |
| PS Ratio | 22.33 |
| Forward PS | 17.87 |
| PB Ratio | 7.24 |
| P/TBV Ratio | 7.24 |
| P/FCF Ratio | 38.15 |
| P/OCF Ratio | 36.11 |
| PEG Ratio | 0.97 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 36.20 |
| EV / Sales | 19.84 |
| EV / EBITDA | 43.86 |
| EV / EBIT | 44.20 |
| EV / FCF | 33.91 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.32 |
| Quick Ratio | 7.73 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.03 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 20.12% |
| Return on Assets (ROA) | 9.37% |
| Return on Invested Capital (ROIC) | 40.16% |
| Return on Capital Employed (ROCE) | 14.40% |
| Weighted Average Cost of Capital (WACC) | 7.81% |
| Revenue Per Employee | $1.49M |
| Profits Per Employee | $818,522 |
| Employee Count | 295 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.62 |
Taxes
| Measure | Value |
|---|
| Income Tax | -14.84M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +79.57% |
| 50-Day Moving Average | 337.46 |
| 200-Day Moving Average | 308.53 |
| Relative Strength Index (RSI) | 53.78 |
| Average Volume (20 Days) | 264,867 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.94M |
| Short Previous Month | 3.48M |
| Short % of Shares Out | 9.92% |
| Short % of Float | 12.43% |
| Short Ratio (days to cover) | 9.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 440.48M |
| Gross Profit | 416.87M |
| Operating Income | 197.75M |
| Pretax Income | 226.62M |
| Net Income | 241.46M |
| EBITDA | 199.29M |
| EBIT | 197.75M |
| Earnings Per Share (EPS) | $7.97 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 845.63M |
| Total Debt | 8.85M |
| Net Cash | 1.09B |
| Net Cash Per Share | $36.96 |
| Equity (Book Value) | 1.36B |
| Book Value Per Share | 45.92 |
| Working Capital | 932.25M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 272.34M |
| Capital Expenditures | -14.56M |
| Depreciation & Amortization | 1.54M |
| Net Borrowing | n/a |
| Free Cash Flow | 257.78M |
| FCF Per Share | $8.71 |
Margins
| Measure | Value |
|---|
| Gross Margin | 94.64% |
| Operating Margin | 44.89% |
| Pretax Margin | 51.45% |
| Profit Margin | 54.82% |
| EBITDA Margin | 45.24% |
| EBIT Margin | 44.89% |
| FCF Margin | 58.52% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.46% |
| Shareholder Yield | -1.46% |
| Earnings Yield | 2.40% |
| FCF Yield | 2.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $395.44 |
| Price Target Difference | 19.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 30.93% |
| EPS Growth Forecast (3Y) | 22.65% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 30.07 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |